MUC16 mutations and prognosis in gastric cancer: A little goes a long way
A partir de l'analyse de données génomiques portant sur 437 puis 256 échantillons de tumeur gastrique issus respectivement du projet "The Cancer Genome Atlas" et d'une cohorte asiatique, cette étude évalue l'association entre des mutations du gène MUC16, codant pour l'antigène CA 125, et la charge mutationnelle de la tumeur ainsi que la survie des patients
Gastric cancer is a global health problem; although incidence rates are declining, it remains the third most common cause of cancer death worldwide. Patients with advanced disease have limited treatment options, and most will live for less than 2 years. Therefore, exploration of gastric cancer disease biology is warranted to identify new targets for treatment. Recent comprehensive molecular analyses have identified distinct subgroups of gastric cancer that may have therapeutic relevance. With the exception of microsatellite-unstable tumors, however, the potential for genomically guided therapy has not been realized.
JAMA Oncology , commentaire, 2017